ARNT2

Across TCGA pan-cancer cohorts, ARNT2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARNT2 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARNT2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARNT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and UCEC are the cancer types where ARNT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.937	0.456	<.001	28	view →
GBM	OS	Quartile	All	1.000	0.783	<.001	15	view →
UCEC	DFS	Median	All	0.979	0.826	.003	14	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARNT2–CCRCC (DFS)

Open the CCRCC breakdown →